home All News open_in_new Full Article

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Total Revenue $19 million, representing +17% growth year over year FDA Approves Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA Latest from VAMOS study demonstrates excess visceral abdominal fat drives cardiovascular risk MONTREAL, April 09, 2025 (GLOBE […]


today 5 d. ago attach_file Culture

attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Culture
attach_file Culture


ID: 3779968625
Add Watch Country

arrow_drop_down